23

Boston Scientific Corp (BSX-N)

ON STOCKCHASE SINCE May 2003

biotechnology/pharmaceutical

Boston Scientific Corp
BSX-N

7 watching

Join the Discussion

Expert Opinions
0 comments
Your Reaction

0 0 0 0 0

What the experts are saying about BSX-N

Signal	Opinion	Expert
BUY	Boston Scientific Corp(BSX-N) April 8, 2019 BSX-N vs. TFX-N. TFX-N is a smaller high growth company. BSX-N is a market leader but recovering from a few years of bad management. He has a low $40s target in a year. He would stick with it. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	BSX-N vs. TFX-N. TFX-N is a smaller high growth company. BSX-N is a market leader but recovering from a few years of bad management. He has a low $40s target in a year. He would stick with it. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Bruce Murray CEO & Chie, The Murray Wealth Gr... Price $37.825 Owned Yes

BUY	Boston Scientific Corp(BSX-N) January 7, 2019 He still loves this name. You can still buy it in the low $30s and he has a target of the low $40s. They are making acquisitions. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	He still loves this name. You can still buy it in the low $30s and he has a target of the low $40s. They are making acquisitions. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Bruce Murray CEO & Chie, The Murray Wealth Gr... Price $34.420 Owned Yes
BUY	Boston Scientific Corp(BSX-N) September 18, 2018 He sold shares in Medtronics (MDT-N) to buy this, which he sees as more of a turnaround play. He sees higher growth prospects in their more targeted business model. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	He sold shares in Medtronics (MDT-N) to buy this, which he sees as more of a turnaround play. He sees higher growth prospects in their more targeted business model. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Bruce Murray CEO & Chie, The Murray Wealth Gr... Price $37.620 Owned Yes
TOP PICK	Boston Scientific Corp(BSX-N) September 18, 2018 The company has raised its growth rate from 5-to-7% to 7-to-10% range. This is a strong turnaround, and he is excited about medical stocks doing better. Yield 0%. (Analysts’ price target is $38.78) biotechnology/pharmaceutical 0 0 0 0 0 0 comments	The company has raised its growth rate from 5-to-7% to 7-to-10% range. This is a strong turnaround, and he is excited about medical stocks doing better. Yield 0%. (Analysts’ price target is $38.78) biotechnology/pharmaceutical 0 0 0 0 0 0 comments Bruce Murray CEO & Chie, The Murray Wealth Gr... Price $37.620 Owned Yes
BUY	Boston Scientific Corp(BSX-N) July 5, 2018 He likes it. They are in cardiac arrhythmia management and cardiology devices. Best in class organic growth. They made 8 acquisitions over the past year or so. Might be a target for an acquisition. One of his favorites option candidates. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	He likes it. They are in cardiac arrhythmia management and cardiology devices. Best in class organic growth. They made 8 acquisitions over the past year or so. Might be a target for an acquisition. One of his favorites option candidates. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Paul Macdonald Chief Inve, Harvest Portfolios G... Price $33.220 Owned Yes
BUY	Boston Scientific Corp(BSX-N) April 2, 2018 On the 5 year chart you can see it is in an uptrend. It is quite tradable. It began to find a lid just under $30. Buy in the low $20s and sell in the high $20’s. Don’t own it for the long run. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	On the 5 year chart you can see it is in an uptrend. It is quite tradable. It began to find a lid just under $30. Buy in the low $20s and sell in the high $20’s. Don’t own it for the long run. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Keith Richards Portfolio , ValueTrend Wealth Ma... Price $26.840 Owned Unknown
HOLD	Boston Scientific Corp(BSX-N) March 21, 2018 No dividend, focussed on cardiac equipment like pacemakers. Have made many acqusitions in past years. Fabulous management. Have driven cost synergies consistently. Beat estimates recently. Forward earnings are 20x. A solid hold. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	No dividend, focussed on cardiac equipment like pacemakers. Have made many acqusitions in past years. Fabulous management. Have driven cost synergies consistently. Beat estimates recently. Forward earnings are 20x. A solid hold. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Paul Macdonald Chief Inve, Harvest Portfolios G... Price $27.660 Owned Yes
COMMENT	Boston Scientific Corp(BSX-N) October 26, 2017 If you own healthcare providers, especially in the hospital supply area, they have been great stocks for a long time. We are all getting older and need more help. Prefers Medtronic (MDT-N) a little better. However, this is another dividend growth story, so you can’t go wrong here. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	If you own healthcare providers, especially in the hospital supply area, they have been great stocks for a long time. We are all getting older and need more help. Prefers Medtronic (MDT-N) a little better. However, this is another dividend growth story, so you can’t go wrong here. biotechnology/pharmaceutical 0 0 0 0 0 0 comments John Burke CEO & CIO, Burke Financial Stra... Price $28.820 Owned No
HOLD	Boston Scientific Corp(BSX-N) June 22, 2016 An extraordinarily well-run company. Great organic growth. A leader in the cardiac rhythm management, and have done that principally organically. The new management in 2012 streamlined operations, became very efficient and enhanced margins on the back of that. This is a company that he wants to continue to own. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	An extraordinarily well-run company. Great organic growth. A leader in the cardiac rhythm management, and have done that principally organically. The new management in 2012 streamlined operations, became very efficient and enhanced margins on the back of that. This is a company that he wants to continue to own. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Paul Macdonald Chief Inve, Harvest Portfolios G... Price $22.660 Owned Yes
BUY	Boston Scientific Corp(BSX-N) April 18, 2016 Thinks this is a good time to be investing in manufacturers of medical devices. There is a whole seasonality that starts in January with a little bit of a pickup in February. They tend to peak every year right around August/September, so there is a bit of time to ride this out. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Thinks this is a good time to be investing in manufacturers of medical devices. There is a whole seasonality that starts in January with a little bit of a pickup in February. They tend to peak every year right around August/September, so there is a bit of time to ride this out. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Hap (Robert) Sn Chief Port, Castlemoore Inc.... Price $19.470 Owned Unknown
DON'T BUY	Boston Scientific Corp(BSX-N) September 14, 2010 In the last 9 months they had their heart defibrillator withdrawn from the US market because of FDA problems. Would steer clear of this one. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	In the last 9 months they had their heart defibrillator withdrawn from the US market because of FDA problems. Would steer clear of this one. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Gordon Reid President, GoodReid Investment ... Price $5.330 Owned No
DON'T BUY	Boston Scientific Corp(BSX-N) March 7, 2007 Had an earnings disappointment. FMV trend is sharply down. When factoring in analysts forecasts, the FMV is about $12.30. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Had an earnings disappointment. FMV trend is sharply down. When factoring in analysts forecasts, the FMV is about $12.30. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Ross Healy Chairman, Strategic Analysis C... Price $15.950 Owned No
BUY on WEAKNESS	Boston Scientific Corp(BSX-N) September 21, 2005 Will have to go to $20.50 before it has a bounce. Has a model price of $31.95 which is a 37/38% differential. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Will have to go to $20.50 before it has a bounce. Has a model price of $31.95 which is a 37/38% differential. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Brian Acker, CA Chief Exec, Acker Finley Inc.... Price $23.170 Owned Unknown
BUY	Boston Scientific Corp(BSX-N) September 6, 2005 In a lawsuit with Johnson and Johnson (JNJ-N), so a lot depends on who wins the case. Their product works better than JNJ and he continues to like it. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	In a lawsuit with Johnson and Johnson (JNJ-N), so a lot depends on who wins the case. Their product works better than JNJ and he continues to like it. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Gavin Graham Trustee, Pointbreak ETFs... Price $26.210 Owned Yes
BUY	Boston Scientific Corp(BSX-N) July 13, 2005 Things look good for them. Won a patent case against Johnson & Johnson (JNJ-N). biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Things look good for them. Won a patent case against Johnson & Johnson (JNJ-N). biotechnology/pharmaceutical 0 0 0 0 0 0 comments Gavin Graham Trustee, Pointbreak ETFs... Price $27.480 Owned Yes

4+

JOIN THE DISCUSSION
4 comments in the last 7 days

Stockchase, in its reporting on what has been discussed by indviduals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc. & Wealthica Financial Technology Inc.